Association of BRCA1/2 mutations with ovarian cancer prognosis: An updated meta-analysis.

about

Association of BRCA1/2 mutations with ovarian cancer prognosis: An updated meta-analysis.

Item

http://www.wikidata.org/entity/Q55377222

description

2018 nî lūn-bûn

@nan

2018年の論文

@ja

2018年学术文章

@wuu

2018年学术文章

@zh-cn

2018年学术文章

@zh-hans

2018年学术文章

@zh-my

2018年学术文章

@zh-sg

2018年學術文章

@yue

2018年學術文章

@zh

2018年學術文章

@zh-hant

name

Association of BRCA1/2 mutations with ovarian cancer prognosis: An updated meta-analysis.

@en

Association of BRCA1/2 mutations with ovarian cancer prognosis: An updated meta-analysis.

@nl

type

Item

label

Association of BRCA1/2 mutations with ovarian cancer prognosis: An updated meta-analysis.

@en

Association of BRCA1/2 mutations with ovarian cancer prognosis: An updated meta-analysis.

@nl

prefLabel

Association of BRCA1/2 mutations with ovarian cancer prognosis: An updated meta-analysis.

@en

Association of BRCA1/2 mutations with ovarian cancer prognosis: An updated meta-analysis.

@nl

P1476

Association of BRCA1/2 mutations with ovarian cancer prognosis: An updated meta-analysis.

@en

P2093

Yong-Wen Huang

http://www.w3.org/2001/XMLSchema#string

P275

Creative Commons Attribution-NonCommercial-NoDerivs 4.0 International

P2860

Risk-reducing salpingo-oophorectomy: a meta-analysis on impact on ovarian cancer risk and all cause mortality in BRCA 1 and BRCA 2 mutation carriers

A phase II evaluation of the potent, highly selective PARP inhibitor veliparib in the treatment of persistent or recurrent epithelial ovarian, fallopian tube, or primary peritoneal cancer in patients who carry a germline BRCA1 or BRCA2 mutation - An

BRCA1/2 mutations associated with progression-free survival in ovarian cancer patients in the AGO-OVAR 16 study.

Cancer statistics, 2010

Extracting summary statistics to perform meta-analyses of the published literature for survival endpoints

The PRISMA statement for reporting systematic reviews and meta-analyses of studies that evaluate health care interventions: explanation and elaboration

Genetic heterogeneity and penetrance analysis of the BRCA1 and BRCA2 genes in breast cancer families. The Breast Cancer Linkage Consortium

Oral poly(ADP-ribose) polymerase inhibitor olaparib in patients with BRCA1 or BRCA2 mutations and recurrent ovarian cancer: a proof-of-concept trial

Evaluation of new platinum-based treatment regimens in advanced-stage ovarian cancer: a Phase III Trial of the Gynecologic Cancer Intergroup.

Aggregate data meta-analysis with time-to-event outcomes.

P304

e9380

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

review article

meta-analysis

P356

10.1097/MD.0000000000009380

http://www.w3.org/2001/XMLSchema#string

P407

English

P433

http://www.w3.org/2001/XMLSchema#string

P478

http://www.w3.org/2001/XMLSchema#string

P5008

ScienceSource

P577

2018-01-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

29480828

http://www.w3.org/2001/XMLSchema#string

P921

Fanconi anemia complementation group proteins

P932

5943891

http://www.w3.org/2001/XMLSchema#string